Citi Maintains Hold on Stryker

Citi is out with its report today on Stryker

, maintaining Hold. In its report, Citi writes, "We rate Stryker Hold/Medium Risk. Fundamentals underlying the hip, knee, and spine implant markets remain soft with the current economic environment still causing postponement of elective procedures." Citi maintains a $68 PT on SYK. At the time of posting, shares of SYK were trading at $47.65, down 0.81% from Monday's close.